Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $19000.0.

  • Compass Therapeutics' Depreciation & Amortization (CF) fell 8671.33% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $399000.0, marking a year-over-year decrease of 3459.02%. This contributed to the annual value of $589000.0 for FY2024, which is 1573.68% down from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Depreciation & Amortization (CF) is $19000.0, which was down 8671.33% from $100000.0 recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Depreciation & Amortization (CF) registered a high of $194000.0 during Q1 2023, and its lowest value of $19000.0 during Q3 2025.
  • Over the past 3 years, Compass Therapeutics' median Depreciation & Amortization (CF) value was $152000.0 (recorded in 2024), while the average stood at $140636.4.
  • Over the last 5 years, Compass Therapeutics' Depreciation & Amortization (CF) had its largest YoY gain of 909.09% in 2025, and its largest YoY loss of 8671.33% in 2025.
  • Compass Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $161000.0 in 2023, then fell by 13.04% to $140000.0 in 2024, then plummeted by 86.43% to $19000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $19000.0 for Q3 2025, versus $100000.0 for Q2 2025 and $140000.0 for Q1 2025.